CAT

886.9

-2.57%↓

320.08

+0.7%↑

GEV.US

995.73

-3.52%↓

RTX

179.28

+1.66%↑

229.01

+2.06%↑

CAT

886.9

-2.57%↓

320.08

+0.7%↑

GEV.US

995.73

-3.52%↓

RTX

179.28

+1.66%↑

229.01

+2.06%↑

CAT

886.9

-2.57%↓

320.08

+0.7%↑

GEV.US

995.73

-3.52%↓

RTX

179.28

+1.66%↑

229.01

+2.06%↑

CAT

886.9

-2.57%↓

320.08

+0.7%↑

GEV.US

995.73

-3.52%↓

RTX

179.28

+1.66%↑

229.01

+2.06%↑

CAT

886.9

-2.57%↓

320.08

+0.7%↑

GEV.US

995.73

-3.52%↓

RTX

179.28

+1.66%↑

229.01

+2.06%↑

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Отворен

1.41 1.44

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.38

Максимум

1.42

Ключови измерители
By Trading Economics
Приходи	-1.5M -19M
Продажби	1.7M 1.5M
EPS	-0.06
Марж на печалбата	-1,250.946
Служители	116
EBITDA	-987K -17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+728.26% upside

Дивиденти
By Dow Jones
Следващи печалби	31.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-173M 454M
Предишно отваряне	-0.03
Предишно затваряне	1.41

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.05.2026 г., 21:33 ч. UTC

Печалби

Correction to Salesforce 1Q Sales, Profit Rise Article

27.05.2026 г., 21:00 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare Agrees to Buy The College of Health Care Professions

27.05.2026 г., 20:18 ч. UTC

Печалби

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27.05.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

27.05.2026 г., 23:08 ч. UTC

Пазарно говорене

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27.05.2026 г., 22:21 ч. UTC

Пазарно говорене

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27.05.2026 г., 21:29 ч. UTC

Горещи акции

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27.05.2026 г., 21:08 ч. UTC

Печалби

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27.05.2026 г., 21:02 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27.05.2026 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27.05.2026 г., 20:55 ч. UTC

Печалби

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.05.2026 г., 20:48 ч. UTC

Печалби

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27.05.2026 г., 20:45 ч. UTC

Печалби

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27.05.2026 г., 20:34 ч. UTC

Придобивния, сливания и поглъщания

Webster Financial Stockholders Approve Sale to Banco Santander

27.05.2026 г., 20:32 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27.05.2026 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27.05.2026 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27.05.2026 г., 20:30 ч. UTC

Печалби

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27.05.2026 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27.05.2026 г., 20:22 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results -- Barrons.com

27.05.2026 г., 20:16 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results -- Barrons.com

27.05.2026 г., 20:13 ч. UTC

Печалби

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27.05.2026 г., 20:13 ч. UTC

Печалби

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27.05.2026 г., 20:13 ч. UTC

Печалби

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27.05.2026 г., 20:12 ч. UTC

Печалби

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27.05.2026 г., 20:12 ч. UTC

Печалби

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

728.26% нагоре

12-месечна прогноза

Среден 11.43 USD 728.26%

Висок 22 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.